UPCC 05126 Testing UGT1A1 Variants and Treatment Related Adverse Events with sacituzumab govitecan-hziy in Patients with Breast Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
80 participants needed
1 Location

Brief description of study

This is a retrospective cohort study which primarily aims to understand if a patients UGT1A1 phenotype affects patients' clinical outcomes following treatment with sacitizumab. Patients will be consented for prospective sample collection to perform genotyping. The genotyping will be performed in a research laboratory and will not be returned to patients or clinicians. Assessment of clinical outcomes will be performed retrospectively through medical records review.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 03 Jun 2026. Study ID: 26-5773
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator